Wave Life Sciences Ltd.

About Wave Life Sciences Ltd.

Wave Life Sciences is dedicated to unlocking the broad potential of RNA medicines to transform human health. The company leverages RNA-targeting modalities, chemistry innovation, and insights into human genetics to develop scientific breakthroughs for treating both rare and common disorders.

Products & Services

PRISM® Platform:A proprietary platform for RNA-targeting modalities and chemistry innovation to develop therapies for various disorders.

Lead Programs:A pipeline of first- or best-in-class RNA therapeutics targeting conditions like Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington's disease, and obesity.

WVE-006:A therapeutic candidate for Alpha-1 antitrypsin deficiency, showing positive updates in the RestorAATion-2 trial.

WVE-007:A candidate targeting INHBE for reducing fat, preserving muscle, and inducing healthy weight loss.

WVE-N531:A treatment for Duchenne muscular dystrophy, demonstrating significant functional benefit and reversal of muscle damage in the FORWARD-53 clinical trial.

PRISM platform

RNA medicines pipeline (Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington’s disease, obesity)

Specialties

RNA Medicines RNA-Targeting Modalities Chemistry Innovation Human Genetics Therapeutics for Rare and Common Disorders RNA-targeting therapeutics Chemistry innovation Human genetics insights

Funding History

No funding data available

This company may be bootstrapped or privately funded

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

No team data available

Team information is not yet available for this company

Recent News